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     Abstract - Copper(II) with 3,5-diisopropylsalicylate, Cu2(3,5-DIPS)4, is a binuclear 
tetracarboxylate–bridged complex. This tan solid has been found to have several 
pharmacological effects which include radioprotectant, radiorecovery, anti-inflammatory, 
anti-convulsant, anti-diabetic, anti-ulcer, anti-cancer and analgesic activities. Some of these 
pharmacological activities are enhanced in the presence of ancillary nitrogen donor ligands 
such as imidazoles, diimines and amines. These pharmacological effects of Cu(II) salicylate 
type complex may be attributed to the anti-oxidative  activities against the reactive oxygen 
species, especially superoxide radical anion (O .2 ), which contribute to the cause of these 
diseases.  
               Histamine (Hst) and cimetidine (Cmt) are biologically active ligands and have 
imidazole and amine nitrogen type ligands and can chelate with metal ions. Cimetidine is a 
drug that has been used as a powerful histamine H2-receptor antagonist in the treatment of 
peptic ulcer. Special interest has been devoted to the interaction of these ligands with 
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copper(II) ion, since some clinical  results support that these  interactions play important 
role in vivo. 
                    We will present our results on the synthesis and spectral characterization of 
mononuclear ternary complexes of the binary copper(II) 3,5-diisopropylsalicylate, 
Cu2(3,5-DIPS)4, complex with histamine and cimetidine and our results on their  activities 
as superoxide dismutase (SOD) mimics. The polyphenol catalytic activities of these binary 
and ternary complexes for catecholase oxidation of 3,5-di-tert-butylcatechol (DTBCH2) to 
corresponding o-benzoquinone(DTBQ) and for oxidative dealkylation of a hindered 2,4,6-
tri-tert-butylphenol (TTBP) will also be  presented.  
 
Introduction 
Copper(II) with 3,5-diisopropylsalicylate,Cu2(3,5-DIPS)4, is a binuclear 
tetracarboxylate–bridged complex. This tan solid has been found to have several 
pharmacological effects which include radioprotectant, radiorecovery, anti-
inflammatory, anti-convulsant, anti-diabetic, anti-ulcer, anti-cancer and 
analgesic activities.   
Some of the above mentioned pharmacological activities of Cu2(3,5-DIPS)4 are 
enhanced in the presence of ancillary nitrogen donor ligands such as imidazoles, 
diimines and amines. These pharmacological effects of Cu(II) salicylate type 
complex may be attributed to the anti-oxidative activities against the reactive 
oxygen species, especially superoxide radical anion (O .2 ), which contribute to 
the cause of these diseases.  
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Histamine (Hst) and cimetidine (Cmt) (structures are shown below) are 
biologically active ligands and have imidazole and amine nitrogen type ligands 
and can chelate with metal ions. 
Histamine is commonly present in tissues of living organisms and has effects on many 
physiological and pathological processes. Cimetidine is a drug that has been used as a 
powerful histamine H2-receptor antagonist in the treatment of peptic ulcer. Special 
interest has been devoted to the interaction of these ligands with copper(II) ion, since 
some clinical  results support that these  interactions play important role in vivo. 
       Histamine        
  Cimetidine 
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Experimental 
Preparation of Cu2(3,5-diisopropylsalicylate)4,Cu2(3,5- DIPS)4, complex: Sodium 
salt of 3,5-diisopropylsalicylate reacts with CuCl2.2H2O in water in 2:1 ratio to 
produce the tan (brown) complex. It has the dimeric paddle wheel structure 
shown below. 
 
 
 
     
 
 
 
 
 
Preparation of binary complexes ,Cu(3,5-DIPS  )2(histamine)2  
and Cu(3,5- DIPS )2(cimetidine)2:  Reaction of binuclear complex  Cu2(3,5- DIPS)4 with 
histamine or cimetidine (molar ratios are 1:4, respectively) in methanol and re-
crystallization  of the products from ethanol produced  blue crystals of the histamine  
adduct  and dark green crystals of cimetidine adduct . 
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 Spectral  and magnetic properties of  ternary complexes: 
 Spectral  and magnetic data(magnetic moment, Uv-visible, IR  and ESR) data are 
consistent with the mononuclear structure for the ternary complexes with histamine and 
cimetidine. 
Based on the these initial spectral results copper atom is coordinated by two  histamine  
or  cimetidine ligands forming an equatorial plane  with two Cu-N of imidazole  rings  and  
two  Cu-N of  NH2 groups of histamines  or two Cu-N  of imidazole  rings  and  two 
 Cu-S of  cimetidines .Two O atoms  from the carboxylate  groups of  two 3,5-di-
isopropylsalicylate  anions   are coordinated on the elongated  axial  positions . 
The  FT-IR spectrum of  Cu(3,5- DIPS )2(cimetidine)2 in the 1700- 1000 cm
-1 region is 
comparable to that reported for the green complex Cu(cim)2(ClO4)2.  In this complex, cim 
acts as a bidendate ligand through N imidazole and S ether atoms. 
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Catecholase mimetic activity. 
The catalytic activities of the complexes for the air oxidation of 3,5-di-tert-butylcatechol 
(DTBCH2) to corresponding o- quinone(DTBQ) were followed spectrophotometrically by 
monitoring the absorbance increase of DTBQ formation at 400nm (ε=1800 M-1 cm-1 ) as a 
function of time. Methanol solution of copper complex (0.3 mL of 0.001M) previously 
saturated with oxygen and 2.0mL of a methanol solution (0.1M) of DTBCH2 were 
combined in a 1 cm quartz cell at room temperature and the absorbance changes at 
400nm were recorded for the first 15 min of the reaction. Complexes 1-4 catalyze the 
oxidation of DTBCH2 to corresponding o-benzoquinone(DTBQ) (Scheme I). 
 
              
 
     
                                                ( Scheme 1 ) 
 
The oxidation activities of the complexes were measured   as micromoles of substrate 
(DBPQ) produced per mg catalyst per min. They are: 0.58 for 1, 0.57 for 2, 0.58 for 3.  
         It has been accepted now that the catecholase activity of mononuclear copper(II) 
complexes follows the mononuclear pathway as we and other researchers showed 
previously. DTBCH2 binds to Cu(II) after its dehydrogenation to form Cu(II) –DTBC complex 
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followed by an internal electron transfer to form Cu(I)–o–semiquinone intermediate 
species. Oxidation by aerobic oxygen occurs to produce o-benzoquinone (DTBQ) and 
Cu(II) complex as shown in the following equations.                     
     Cu(II)complex+DTBC ____→ [Cu(II) (DTBC)2-]                          (1) 
     Cu(II)(DTBC)2-]      electron transfer  [Cu(I)(DTBSQ)-]           (2)  
     [Cu(I) (DTBSQ)-]     oxidation   Cu(II) complex + DTBQ     (3) 
 
The formation of copper(I)- 3,5-di-t-butyl o–semiquinone intermediate during the 
oxidation process was demonstrated in this study by following the Uv-visible spectral 
changes of the catalytic reaction mixture. Copper(II) complex (0.02 mmol) and  DTBCH2   
(0.44 mmol) were mixed in 20 mL degassed methanol under nitrogen and the Uv-visible 
spectrum of the intense green solution was recorded. Three absorption bands appeared 
with time: one very broad band with moderate intensity centered at about 770 nm, a 
second band with less intensity at about 570 nm and a third sharp and very intense band 
at about 385 nm. The first and third  bands at about 770 and 385 nm, respectively, are the 
ligand DTBSQ- bands (Eq.2) and comparable with those reported previously for Cu(I)- 
DTBSQ species  The second band at about 570 nm is assigned to the catecholato to 
Copper(II) charge transfer which is in equilibrium with  Cu(I)-DTBSQ- (Eq.2) and analogy to 
assignment made for other Copper(II)-catecholate complexes. When this solution was 
exposed to aerial oxygen, the bands at 770 nm and 570 nm decayed and the band at 385 
nm shifted to ca.400 nm, which is characteristic of DTBQ. Methanol was evaporated from 
this reaction mixture, the precipitate was extracted with anhydrous diethylether and 
filterd  (copper complexes do not dissolve in ether). Evaporation of the ether filtrate gave 
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DTBQ, whose IR { ν(CO) =1665 cm_1 }, Uv-vis in methanol solution gave band at 400nm, 
and  1H NMR {CDCl3: δ ppm 1.20(9H), 1.26(9H), 6.20 (1H), 6.98 (1H)}  spectra were 
compared with those of authentic DTBQ. 
 
 Oxidative dealkylation of 2, 4, 6-tri-tert-butylphenol  (TTBP).  
The oxygenation reaction of TTBP with the copper(II)complex as a catalyst and the initial 
formation of the 2,4,6-tri-tert- butylphenoxyl radical was followed spectrophoto-
metrically. An oxygen saturated methanol solution of copper(II) complex (0.3mL of 1×10-
3M) was mixed with 2mL (0.05M) of  TTBP dissolved in methanol and the formation of 
phenoxyl  radical was followed at 400nm, since TTB phenoxyl radical showed bands in 
visible region at about 634nm , 400nm  and 382nm. 
The mechanism for oxygenation dealkylation  of  TTBP is summarized in Scheme (II)  
shown  below: 
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 These products [A and B] are obtained in larger scale, separated and characterized by IR, 
Uν-visible and NMR spectroscopy. A 0.1mmol of copper complex dissolved in methanol or 
CH2Cl2 and 2mmol (0.525g) of TTBP dissolved in the same solvent, mixed with toluene in 
1:1 ratio, was stirred under oxygen for 3 hrs. The reaction mixture was 
separated by silica gel column using CH2Cl2: n-hexane as eluent solvent (1:20 ratio then 
increased gradually to 1:2 ratio). In addition to the above mentioned major products (A) 
and (B) another 3 products in small quantities were obtained and not identified. The 
spectral properties of the products (A) and (B) are summarized below: 
IR spectra: products (A) and (B) exhibited two stretching bands for the carbonyl groups at  
1665 and at 1620 cm-1 for (A) and at 1655 and at 1600 cm-1 for (B). Uν-visible in methanol 
solutions showed absorption band at 400nm for (A) and at 450nm for (B). NMR spectra in 
CDCl3 for (A) exhibited protons chemical shifts (ppm) of tertiary butyl groups at 1.20 (9H) 
and at 1.26 (9H) and peaks at 6.21 (1H) and 6.96 (1H) for the protons at 3 and 5 positions. 
NMR spectrum of (B) exhibited peaks at 1.27 ppm (18H) for the two tertiary butyl groups 
and a peak at 6.50ppm (2H) for the two protons at 3 and 5 positions.  
 
 
 Superoxide dismutase activity 
         The superoxide dismutase mimetic activity of the binary complexes 2 and 3, was 
measured using the xanthine-xanthine oxidase – nitroblue tetrazolium (NBT) assay 
system.  A plot of NBT percent inhibition with an increase in concentration of complex 2 is 
shown in Fig.1. The determined IC50 values for the complexes under investigation are 
given in Table 1. In addition, to ascertain the effectiveness of the present complexes as 
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functional SOD mimics, we compared the IC50 of several anti-inflammatory drug 
complexes which were previously determined using the NBT method under the same 
conditions (Table 1). The IC50 values obtained for complexes 2 and 3 indicated that their 
SOD activities lie in the high activity region of the spectrum exhibited by copper 
complexes. The mechanism proposed for dismutation of superoxide anions in both the  
native Cu, Zn–SOD and low molecular weight Cu(II) mimics involved the initial binding of 
superoxide to Cu(II) ion which allows an electron transfer  to occur  from O2
.- to  Cu(II)  
[Eq.1] . The Cu(I) complex formed is oxidized back to Cu(II) complex by another molecule 
of O2
·− [Eq.2]                                                                        
                                     Cu2++O 
 
 → Cu+ + O2,    (1) 
                         Cu+ + O 
 
+2H+ → Cu2+ + H2O2   (2) 
 Some factors were discussed which may involve in the differing dismutation activities 
shown by different copper complex mimics in vitro. A fast exchange of molecules 
coordinated axially to copper atom and limited steric hindrance to the approach of the 
O 
 
 anion are considered essential requirements for the successful binding of the O  
 
. The 
flexibility of copper complex to geometrical arrangement changes, during the redox 
cycling of Cu(II) ion, which facilitates the interaction of the O  
 
 is also important. The 
geometry of Cu(II) in SOD enzyme changes from distorted square pyramidal to distorted 
tetrahedral Cu(I) during dismutation of superoxide anion. In addition, the nature of 
coordinated ligands to copper is also playing an important role in enhancing the SOD 
activity of the copper complex mimic. The favorable response of the π-electrons of the 
coordinated ligands in stabilizing the Cu(II) – O 
 
 interaction and ligands that have groups 
which are capable to stabilize this interaction through hydrogen bond formation with the 
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coordinated O 
 
 anion, give rise to better SOD mimics. The  SOD activity observed for the 
binary complex 1 is explained in terms of a fast exchange of axial solvent molecules  and 
also related to possible cooperation of both Cu(II) centers, in close proximity, in free 
radical binding and electron transfer. One Cu(II) may resemble the role of Zn(II) in the 
native SOD, through the imidazolate bridge, in controlling the electron density at the 
redox active Cu(II). The relatively high SOD mimic activity exhibited by complexes 2 and 3 
(Table 1) may be explained in terms of its tetragonally distorted structure having 
mononuclear units with CuN2N2+O2 chromophore. The relatively weak axial coordination 
of carboxylate  oxygen  atoms of 3,5- di-isopropylsalicylate  anions  are readily dissociated 
in solution to provide axial sites on Cu(II) for O 
 
 bonding. The dissociation would also 
facilitate any necessary geometrical changes induced by O 
 
 bonding during catalysis as in 
the native SOD. The higher SOD activity of the histamine adduct  may be attributed to the 
presence of NH2 group in the  histamine  adduct (2) that is coordinated to copper which 
can assist and stabilize the axial coordination of the O 
 
 anion to copper atom through 
hydrogen bonding formation, which will result in activity enhancement.  The IC50%  values 
exhibited by complexes 1, 2 and 3  (Table1) fall in the lower end of the range (0.17-29 μM 
)  previously  reported for copper(II)  complexes with salicylate derivatives, an IC50% range 
of which was used therapeutically as anti-inflammatory agents in human and veterinary 
medicine. In addition,  these complexes  are potent SOD mimics considering their low 
molecular weight when compared to that of the native Cu,Zn-SOD 
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Fig. 1.  Percentage of inhibition reduction of NBT against concentration of  
             complex 2. 
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         Table 1. SOD  Mimetic Activity of Cu(II) Complexes 
 
         Complex                                                                        IC50(μ M) 
 
       Cu2(3,5-DIPS)4                                                                     1.0 – 3.0   
       Cu(3,5-DIPS)2(Hst)2                                                                        0.50                       
       Cu(3,5-DIPS)2(Cmt)2                                                                                1.70 
        Cu(Cmt)2
+1/+2                                                                        0.4-4.0 
       Cu(Hsal)2(benzimidazole)2                                                  0.74 
       Cu(sal)(phenanthroline)                                                      1.01 
       Cu2 (Salicylate)4                                                                    1.30 
       Cu2 (aspirinate)4                                                                    2.13 
      Cu2(Indomethacin)4(DMF)2                                                  0.23 
       Cu2(Tolfenamate)4(DMF)2                                                   1.97 
       Cu,Zn-SOD enzyme                                                               0.04 
 
 
